PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.

about

PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.

Item

http://www.wikidata.org/entity/Q50213474

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.

@en

PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.

@nl

type

Item

label

PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.

@en

PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.

@nl

prefLabel

PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.

@en

PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.

@nl

P1476

PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.

@en

P2093

Eriko Yokoi

http://www.w3.org/2001/XMLSchema#string

Hiromasa Kuroda

http://www.w3.org/2001/XMLSchema#string

Kae Hashimoto

http://www.w3.org/2001/XMLSchema#string

Katsumi Kozasa

http://www.w3.org/2001/XMLSchema#string

Kenjiro Sawada

http://www.w3.org/2001/XMLSchema#string

Mahiru Kawano

http://www.w3.org/2001/XMLSchema#string

Naoko Komura

http://www.w3.org/2001/XMLSchema#string

Seiji Mabuchi

http://www.w3.org/2001/XMLSchema#string

Tadashi Kimura

http://www.w3.org/2001/XMLSchema#string

Yuri Matsumoto

http://www.w3.org/2001/XMLSchema#string

P2860

Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment

Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy

Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study

Signatures of mutational processes in human cancer

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.

Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity.

Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer.

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

P304

805-817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2017-0046

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28877631

http://www.w3.org/2001/XMLSchema#string